Exhibit 10.1

 

Novo Integrated Sciences Inc./ Novo Healthnet Limited

11120 NE 2nd Street, Suite 200

Bellevue, Washington 98004

 

Oct. 10, 2018

 

CannaPiece Group Inc.

2240 Midland Ave., Unit 103

Toronto, Ontario

M1P 4R8

Attention: Ray Rasouli

 

Re: Letter of Intent for the purchase of Novo Integrated Sciences Inc. shares
and the contemplated merger of Novo Integrated Sciences Inc. and CannaPiece
Group Inc.

 

This binding letter of intent (“LOI” or “Letter”), is to generally record terms
and conditions of the proposed agreement whereby Novo Healthnet Limited, an
Ontario corporation (“NHL”) will enter into a joint venture relationship with
CannaPiece Group Inc. (“CG”), a corporation incorporated under the laws of
Ontario. In addition, CG will also invest into NHL’s parent company, Novo
Integrated Sciences Inc. (“NVOS”), a company incorporated in the state of Nevada
whose shares are traded publicly in the OTCQB. CG and NVOS will also enter into
a share exchange agreement resulting in each company having mutual interest in
the other.

 

This Letter is a binding agreement between us. Notwithstanding the foregoing,
the parties acknowledge and confirm it is their intention that this Letter will
serve only as a preliminary interim agreement in relation to the matters
described herein, which will apply until the Definitive Agreement (as defined
below) is concluded.

 

The following paragraphs reflect our preliminary agreement with respect to the
Transaction (as defined below):

 

  1. Structure: The parties intend to enter into a subscription agreement and a
share exchange or other similar business arrangement (the “Transaction”) in
which:

 

  i. Prior to, and as a condition of closing, CG will take the necessary and
appropriate steps required to ensure that the corporation is properly
registered, and all subsidiaries properly organized and identified.         ii.
CG will purchase through a subscription agreement five million Canadian dollars
(CAD $5,000,000) in value of NVOS shares. The share price will be determined by
a thirty-day closing average based on the thirty day period ending on the date
of execution in counterpart of this LOI, and the application of a market
acceptable discount to the determined average. In addition, CG, NHL and NVOS
will enter into a share exchange arrangement whereby (a) NHL will own or control
twenty five percent (25%) of all common stock of CG upon closing of the
Transaction, and (b) CG will own or control twenty-five million Canadian dollars
(CAD $25,000,000) worth of NVOS stock, which value shall be established by a
30-day closing average based on the thirty day period ending on the date of
execution of this LOI, and the application of a market acceptable discount to
the determined average. The twenty-five million Canadian dollar (CAD
$25,000,000) value is based on a pre-revenue, post-licensing evaluation of CG in
the amount of one hundred million Canadian dollars (CAD $100,000,000).

 

   

 

 

  iii. NVOS shall have the right to appoint one board member on the CG board of
directors and CG shall have the right to appoint one board member on the NVOS
board of directors.         iv. CG will roll-out a clinic cannabis access
program in all applicable Novo network clinics.         v. CG will enter into a
case conference program with applicable Novo network stakeholders.

 

  2. Due Diligence: The parties will work promptly to carry out all required due
diligence in respect of the Transaction, including without limitation, the
completion of standard business, legal and other inquiries and a review of
applicable laws and regulations. The parties will afford each other, its
employees, auditors, legal counsel, and other authorized representatives all
reasonable opportunity and access during normal business hours to inspect and
investigate the business and financial affairs of the other party.         3.
Definitive Agreement. We mutually agree to proceed reasonably and in good faith
toward the negotiation and execution of definitive documentation which shall
contain the terms and conditions set out in the LOI and such other terms,
conditions, indemnities, representations, warranties, covenants as are customary
for transactions of this nature (the “Definitive Agreement”). The parties shall
cooperate in structuring the Transaction in the most effective manner having
regard to applicable tax, corporate, and securities laws. Upon the execution and
delivery of the Definitive Agreement, it will supersede this Letter.         4.
Regulatory Approvals and Contractual Consents: Each of the parties will use its
commercially reasonable best efforts to obtain:

 

  i. the necessary board approvals and shareholder approvals for the Transaction
prior to the execution of the Definitive Agreement; and         ii. all
necessary regulatory approvals (including approvals from any licensing
authorities) and third-party consents and the necessary shareholder approvals
prior to the closing of the Transaction and to cooperate in providing any
submissions necessary to effect the Transaction.

 

  5. Other Conditions. The Definitive Agreement shall include, but will not be
limited to, the following terms and conditions, and this Letter is similarly
subject to the following terms and conditions:

 

  i. closing of the Transaction will be conditional upon the parties having
completed their respective due diligence investigations, the results of which
are satisfactory to the parties their sole discretion;         ii. CG will
continue toward full cannabis license producer status and will not have the
licensing application compromised in any way;         iii. NVOS shares derived
from the share exchange transaction shall be held in escrow until CG receives
Licensed Producer (“LP”) status.         iv. closing of the Transaction will be
condition upon the parties receiving all regulatory approvals required to
complete the Transaction;         v. the parties agree to cooperate to prepare
for filing the necessary current reports with the Securities and Exchange
Commission (the “Exchange”) with respect to the Transaction, including a Form
8-K, within the regulatory required time limits following the closing of the
Transaction

 

   

 

 

  vi. closing of the Transaction will be conditional upon the representations
and warranties contained in the Definitive Agreement being true and correct in
all material respects as of closing; and         vii. no material adverse change
shall have occurred in the business, assets, liabilities, results, financial
condition, affairs or prospects of either party from the date hereof to the
closing of the Transaction.

 

  6. Adjustment of Officers and Directors: At the closing of the Transaction,
both parties will appoint directors to each other’s boards as described above.  
      7. Confidentiality: Each party agrees that, subject to compliance with
applicable laws, it will keep confidential, and not release to any other person,
this proposal, the contents of this Letter of Intent and any of the proprietary
business, technical or other information obtained by it during its due diligence
inquiries and any related negotiations. Each party’s obligations in this respect
shall survive the closing of the Transaction or any termination of the proposed
Transaction between the parties or the termination of this LOI.         8.
Disclosure: No public announcement concerning the Transaction contemplated
herein or the status of the discussions between the parties hereto shall be made
by either party unless and until the same has been approved by both parties
hereto, or unless such disclosure is required by any government laws, rules or
regulations, by any government regulatory authorities or any stock exchange
having jurisdiction over either party, provided that prior written notice is
provided to the other party respecting such disclosure or public announcement
and such party has been provided reasonable opportunity to review and comment on
the proposed disclosure.         9. Costs: The parties will each be solely
responsible for and bear their own respective expenses, including, without
limitation, expenses of legal counsel, accountants, and other advisors, incurred
at any time in connection with pursuing or consummating the Transaction. Each
party’s obligations in this respect shall survive the closing of the Transaction
or any termination of the Transaction between the parties. It is expressly
understood that both parties’ counsel will be together responsible for preparing
the documents required to complete the Transaction, including the filing
statement required to be filed with the Exchange in connection with the
Transaction.         10. Exclusivity: The parties hereby agree that until the
Termination Date (as defined below) or the date the parties enter into the
Definitive Agreement, each party and their respective directors, officers,
employees, agents and representatives will not, directly or indirectly:

 

  i. solicit, initiate or encourage the initiation of any expression of
interest, inquiries or proposals regarding, constituting or that may reasonably
be expected to lead to any merger, amalgamation, take-over bid, tender offer,
arrangement, recapitalization, liquidations, dissolution, share exchange, sale
of material assets involving the parties or a proposal or offer to do so (the
“Acquisition Proposal”) (including without limitation, any grant of an option or
other right to take any such action);         ii. participate in any discussions
or negotiations regarding an Acquisition Proposal;

 

   

 

 

  iii. accept or enter into, or propose publicly to accept or enter into, any
agreement, letter of intent, memorandum of understanding or any arrangement in
respect of an Acquisition Proposal; and         iv. otherwise cooperate in any
way, assist or participate in, facilitate or encourage any effort or attempt by
any person to do any of the foregoing.

 

  11. Binding Effect: The consummation of the Transaction is subject to the
entry of the Definitive Agreement. The Definitive Agreement is subject to the
board approval of each of the parties.         12. Termination: If the
Definitive Agreement is not negotiated and executed by both parties on or before
November 15, 2018 or such other date as agreed to by the parties (the
“Termination Date”), then the terms of this LOI will be of no further force or
effect except for Section 7 (Confidentiality), Section 9 (Costs) and Section 13
(Governing Laws). Section 7 (Confidentiality) and Section 13 (Governing Laws)
will remain in effect for a period of one (1) year following the date this LOI
is terminated.         13. Governing Laws: This Letter of Intent will be
governed by and be construed in accordance with the laws of the Province of
Ontario and the federal laws of Canada applicable therein. The parties agree
that any dispute arising out of or relating to this LOI shall be subject to the
exclusive jurisdiction of the courts in and for the Province of Ontario and each
party agrees to submit to the personal and exclusive jurisdiction and venue of
such courts. Governing law and jurisdiction regarding the Definitive Agreement
shall be negotiated between and agreed to by the parties and set out in the
Definitive Agreement.         14. Counterparts and Delivery: This Letter may be
executed in any number of counterparts, each of which shall be deemed an
original and all of which, taken together, shall constitute one and the same
instrument. This Letter may be executed and delivered by facsimile or electronic
transmission and the parties may rely on a facsimile or electronic signature as
though it were an original signature.

 

   

 

 

If the terms outlined above are acceptable to you please sign and date this
Letter in the space provided below and return a signed copy to the undersigned.

 

  Very truly yours,         Novo Integrated Sciences Inc. and Novo Healthnet  
Limited         By /s/ Robert Mattacchione     Robert Mattacchione, Chairman,
Novo Healthnet Limited         By /s/ Chris David     Chris David, President,
Novo Integrated Sciences Inc.         ACKNOWLEDGED AND AGREED to on October 16,
2018:         CannaPiece Group Inc.         By /s/ Ahmad Rasouli      Ahmad
Rasouli, CEO